Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

23. April 2019 16:05 ET | Quelle: Myriad Genetics, Inc.

Myriad to Announce Fiscal Third-Quarter 2019 Financial Results on May 7, 2019

SALT LAKE CITY, April 23, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that it will hold its fiscal third-quarter 2019 sales and...
23. April 2019 07:05 ET | Quelle: Myriad Genetics, Inc.

Myriad to Present Multiple Women’s Health Studies at the 2019 American College of Obstetricians and Gynecologists Annual Meeting

SALT LAKE CITY, April 23, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that its Myriad Women’s Health business unit will present...
17. April 2019 07:05 ET | Quelle: Myriad Genetics, Inc.

Myriad Genetics Named to Forbes 2019 List of America's Best Midsize Employers and the Women Tech Council’s 2019 Shatter List

SALT LAKE CITY, April 17, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced today announced that the company was named to...
09. April 2019 07:05 ET | Quelle: Myriad Genetics, Inc.

Myriad Genetics Submits First Module of the Premarket Approval Application to FDA for the myChoice® HRD CDx Test

SALT LAKE CITY, April 09, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that it has submitted the first module of its premarket...
04. April 2019 07:05 ET | Quelle: Myriad Genetics, Inc.

Myriad, AstraZeneca and Merck Expand Companion Diagnostic Partnership

SALT LAKE CITY, April 04, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that it has expanded its companion diagnostic...
02. April 2019 07:05 ET | Quelle: Myriad Genetics, Inc.

Myriad Women’s Health to Highlight New Studies Demonstrating the Superior Clinical Performance of the Foresight® and Prequel™ Prenatal Tests

SALT LAKE CITY, April 02, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that its Myriad Women’s Health business unit will...
21. März 2019 07:05 ET | Quelle: Myriad Genetics, Inc.

Myriad to Present 18 Studies at the 2019 Annual Clinical Genetics Meeting

SALT LAKE CITY, March 21, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that its Myriad Women’s Health business unit will present...
14. März 2019 08:01 ET | Quelle: Myriad Genetics, Inc.

Myriad’s myPath® Melanoma Test Receives Medicare Coverage

SALT LAKE CITY, March 14, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that the Medicare Administrative Contractor...
06. März 2019 07:05 ET | Quelle: Myriad Genetics, Inc.

Myriad Announces Publication of Expanded Carrier Screen Study in Genetics in Medicine

SALT LAKE CITY, March 06, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that its Myriad Women’s Health business unit has...
26. Februar 2019 13:10 ET | Quelle: Myriad Genetics, Inc.

Myriad’s BRACAnalysis CDx® Test Successfully Identified Patients with Metastatic Pancreatic Cancer Who Benefitted from Treatment with Olaparib

Myriad Will Seek FDA Approval of BRACAnalysis CDx as a Companion Diagnostic for Olaparib in this Patient Population SALT LAKE CITY, Feb. 26, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:...

Vorherige Seite

Nächste Seite